Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT-Reference-Cited by-同舟云学术

Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT

Published:2014-03-01 Issue:4 Volume:9 Page:339-347
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Boers-Sonderen Marye J.,de Geus-Oei Lioe-Fee,Desar Ingrid M. E.,van der Graaf Winette T. A.,Oyen Wim J. G.,Ottevanger Petronella B.,van Herpen Carla M. L.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-014-0309-x.pdf

Reference32 articles.

1. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281. doi: 10.1056/NEJMoa066838

2. Gridelli C, Maione P, Rossi A (2008) The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13(2):139–147. doi: 10.1634/theoncologist.2007-0171

3. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23(23):5314–5322

4. Fleming G, Ma C, Huo D, Sattar H, Tretiakova M, Lin L, Hahn O, Olopade FO, Nanda R, Hoffman P, Naughton MJ, Pluard T, Conzen S, Ellis M (2012) Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 136(2):355–363. doi: 10.1007/s10549-011-1910-7

5. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123(1):19–26

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options;Reproductive Sciences;2024-04-24

2. Imaging glucose metabolism to reveal tumor progression;Frontiers in Physiology;2023-02-02

3. A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies;Cancers;2022-03-31

4. Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts;Molecular Imaging;2021-05-25

5. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer;Cancer Drug Resistance;2021